title: Undertreatment of tracheal carcinoma: multidisciplinary audit of epidemiologic data.
abstract: National epidemiologic data were examined to determine the eligibility for curative therapy in tracheal carcinoma. An expert audit of primary tracheal carcinomas registered from 2000 to 2005 with the Netherlands Cancer Registry (NCR) included blinded patient data and radiographic review to assess diagnosis and resectability. Actual treatment was compared with the opinions of a multidisciplinary panel (Radboud panel) and a second reviewer. Of 101 NCR-registered primary tracheal carcinomas, the Radboud panel diagnosis was metastatic disease or local extension of adjacent tumors in 34. Seventeen cases were excluded for missing data. In 50 cases confirmed by panel and a second reviewer, actual treatment consisted of surgery in 12 (24%), radiotherapy in 29 (58%), endobronchial treatment in 6 (12%), and observation in 3 (6%). Both panel and second reviewer identified 16 additional surgical candidates, a total of 28 (56%) of 50. Treatment recommendations of panel and second reviewer disagreed in four cases (8%). One-third of NCR-registered primary tracheal carcinomas were misclassified nontracheal primary tumors involving the trachea. A majority of cases meeting audit criteria for diagnosis and surgical resection was treated with other modalities. Interreviewer disagreement was small. The audit of a national cancer registry suggests that incorrect diagnosis and undertreatment are common in rare airway tumors.
authors.affiliation: Department of Oto-Rhino-Laryngology and Head and Neck Surgery, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands. j.honings@kno.umcn.nl
authors.forename: Jimmie
authors.initials: J
authors.lastname: Honings
authors.forename: Henning A
authors.initials: HA
authors.lastname: Gaissert
authors.forename: Ad F T M
authors.initials: AF
authors.lastname: Verhagen
authors.forename: Jos A A M
authors.initials: JA
authors.lastname: van Dijck
authors.forename: Henricus F M
authors.initials: HF
authors.lastname: van der Heijden
authors.forename: Lya
authors.initials: L
authors.lastname: van Die
authors.forename: Johan
authors.initials: J
authors.lastname: Bussink
authors.forename: Johannes H A M
authors.initials: JH
authors.lastname: Kaanders
authors.forename: Henri A M
authors.initials: HA
authors.lastname: Marres
mesh_terms: D000230:Adenocarcinoma / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018287:Carcinoma, Large Cell / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D018288:Carcinoma, Small Cell / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008485:Medical Audit / Q000706:statistics & numerical data*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D009367:Neoplasm Staging; D009426:Netherlands / Q000453:epidemiology; D010348:Patient Care Team / Q000458:organization & administration*; D014134:Tracheal Neoplasms / Q000175:diagnosis / Q000453:epidemiology* / Q000628:therapy*